Akonni Biosystems Awarded $3M Akonni Biosystems Challenge Grant to Develop Rapid Molecular Test for Genotyping MDR/XDR-TB
9/28/2010 12:03:15 PM
FREDERICK, Md.--(BUSINESS WIRE)--Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated genetic testing devices for complex infectious and human diseases, today announced receipt of a nearly $3 million Challenge Grant from the National Institutes of Health (NIH), a new program made possible under the American Recovery and Reinvestment Act (ARRA). Selected from well over 20,000 applications, these funds will enable Akonni to advance the development of its multi-drug resistant/extensively drug-resistant (MDR/XDR) genotyping test through pre-clinical testing at several international field sites, including sites such as the Medical Research Council of South Africa (MRC).
comments powered by